Pros and Cons of Genus plc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 2.330% | 3.614% | 17.007% | 53.571% | 17.007% | 8.176% | -39.649% |
| Ironwood Pharmaceuticals | -1.000% | -1.896% | 14.365% | 102.941% | 55.639% | -60.534% | -51.006% |
| Novocure Ltd | -1.630% | -7.561% | -10.371% | -56.564% | -11.557% | -88.507% | -93.072% |
| Iovance Biotherapeutics Inc. | -6.440% | -9.846% | 3.867% | -59.271% | -6.008% | -69.863% | -94.335% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat